Sanofi's New Cancer Drug Could Help Deliver a Big Payday
Sanofi (NASDAQ: SNY) believes it has a potential blockbuster in its innovative new cancer-fighting drug. If the company is right, investing now could pay off handsomely in the future, for those with patience.
Sanofi's rilzabrutinib performed well in its phase 3 clinical trial, meaning the company can now apply for approval. The drug is a type of BTK inhibitor that combats disorders found in B lymphocytes, also known as B cells. BTK inhibitors have shown effectiveness as a treatment for such diseases as non-Hodgkin lymphomas.
The excitement over its clinical trial success stems from its efficacy compared to the competition. Rilzabrutinib works at a smaller dosage and has fewer unwanted side effects. Those traits immediately make the drug promising in the marketplace.
Source Fool.com
